MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...

General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to ...

Eisai and Biogen have announced UK MHRA approval for Leqembi for intravenous (IV) maintenance dosing to treat early Alzheimer ...

The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.

Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.” ...

The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking the ...

If successful in the Phase III trial, VK2735 would enter direct competition with established dual agonists such as Eli ...